Literature DB >> 26241540

124 cases of clinical analysis of children with viral myocarditis.

L Niu1, X-J An, J Tian, Y Wang.   

Abstract

OBJECTIVE: A study on clinical characteristics, diagnostic methods of children's viral myocarditis (VMC) and analysis of the effect of VMC is carried out. PATIENTS AND METHODS: A retrospective analysis of the clinical data of 124 cases of children with VMC from January 2008 to March 2011 in Xuzhou Children's Hospital is conducted.
RESULTS: The age of onset of 1 VMC is less than 1 year old with the majority, fever, precordial pain, and fatigue as the main manifestation, auxiliary examination of abnormal electrocardiogram (ECG) in 110 cases, accounting for 88.71%, the positive rate of dynamic ECG is 92.31%, and abnormal rate of myocardial enzyme examination is 96.77%. The effective rate of treatment is 94.35%, and the effective rate of treatment of creatine phosphate sodium is 100%.
CONCLUSIONS: For childhood, especially 1 year old children with viral infection in clinical, attention should be paid to the VMC performance, suspected children should be timely ECG, dynamic ECG and myocardial enzyme examined with diagnosis and early treatment. The myocardial protection of creatine phosphate sodium has definite therapeutic effect on VMC of children.

Entities:  

Mesh:

Year:  2015        PMID: 26241540

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  2 in total

1.  Diagnostic Performance of Serum CK-MB, TNF-α and Hs-CRP in Children with Viral Myocarditis.

Authors:  Jia Chen; Yuanying Deng
Journal:  Open Life Sci       Date:  2019-03-20       Impact factor: 0.938

2.  Clinical effects of tanshinone IIA sodium sulfonate combined with trimetazidine and levocarnitine in the treatment of AVMC and its effects on serum TNF-α, IL-18 and IL-35.

Authors:  Pengliang Xu; Lei Ji; Shuang Tian; Fumei Li
Journal:  Exp Ther Med       Date:  2018-08-31       Impact factor: 2.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.